Clinical trial
VivaGel™ in Healthy Young Women
NCT00331032 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00331032 |
|---|---|
| Title | VivaGel™ in Healthy Young Women |
| Official title | An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3 Percent w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Herpes Simplex II |
| Intervention type | Drug |
| Interventions | 3% w/w SPL7013 Gel, Placebo |
| Enrollment | 56 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | May 29, 2006 |
| Last update posted | Aug 23, 2013 |
| Countries | Kenya, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: